Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 9/20 | 0.74 |
| ▸ | CHRM1 | P11229 | 5/20 | 0.74 |
| ▸ | HRH1 | P35367 | 4/20 | 0.74 |
| ▸ | ADRA2A | P08913 | 4/20 | 0.74 |
| ▸ | HTR2A | P28223 | 4/20 | 0.74 |
| ▸ | CHRM2 | P08172 | 4/20 | 0.74 |
| ▸ | CHRM4 | P08173 | 4/20 | 0.74 |
| ▸ | CHRM5 | P08912 | 4/20 | 0.74 |
| ▸ | CHRM3 | P20309 | 4/20 | 0.74 |
| ▸ | DRD1 | P21728 | 4/20 | 0.74 |
| ▸ | KCNH2 | Q12809 | 4/20 | 0.74 |
| ▸ | DRD4 | P21917 | 4/20 | 0.74 |
| ▸ | DRD3 | P35462 | 4/20 | 0.74 |
| ▸ | CYP1A2 | P05177 | 4/20 | 0.74 |
| ▸ | CYP2D6 | P10635 | 4/20 | 0.74 |
| ▸ | HRH2 | P25021 | 3/20 | 0.74 |
| ▸ | HTR1A | P08908 | 3/20 | 0.74 |
| ▸ | ADRA2B | P18089 | 3/20 | 0.74 |
| ▸ | ADRA2C | P18825 | 3/20 | 0.74 |
| ▸ | HTR2C | P28335 | 3/20 | 0.74 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29969899 | 1.00 | DRD2 (0.74) | DRD2CHRM1HRH1ADRA2AHTR2A | |
| SCHEMBL3409689 | 0.87 | DRD2 (0.80) | DRD2CHRM1HRH1ADRA2AHTR2A | |
| Amoxapine SCHEMBL33950 | 0.85 | DRD2 (1.00) | DRD2CHRM1HRH1ADRA2AHTR2A | |
| Amoxapine SCHEMBL29354942 | 0.85 | DRD2 (1.00) | DRD2CHRM1HRH1ADRA2AHTR2A | |
| Amoxapine SCHEMBL29482386 | 0.85 | DRD2 (1.00) | DRD2CHRM1HRH1ADRA2AHTR2A | |
| SCHEMBL2738976 | 0.85 | DRD4 (0.82) | DRD2CHRM1HRH1ADRA2AHTR2A | |
| SCHEMBL2615197 | 0.85 | DRD2 (0.74) | DRD2CHRM1HRH1ADRA2AHTR2A | |
| SCHEMBL3411889 | 0.85 | DRD2 (0.74) | DRD2CHRM1HRH1ADRA2AHTR2A | |
| SCHEMBL3405535 | 0.85 | DRD2 (0.63) | DRD2CHRM1HRH1ADRA2AHTR2A | |
| Amoxapine SCHEMBL29370074 | 0.85 | DRD2 (1.00) | DRD2CHRM1HRH1ADRA2AHTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 70 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7622461-B2 | Amino substituted diaryl[a,d]cycloheptene analogs as muscarinic agonists and methods of treatment of neuropsychiatric disorders | ACADIA PHARMACEUTICALS INC. (US) | 2009-11-24 | — | — | US | claimed |
| US-20090239840-A1 | AMINO SUBSTITUTED DIARYL[a,d]CYCLOHEPTENE ANALOGS AS MUSCARINIC AGONISTS AND METHODS OF TREATMENT OF NEUROPSYCHIATRIC DISORDERS | ACADIA PHARMACEUTICALS, INC. (US) | 2009-09-24 | — | — | US | claimed |
| EP-1865962-A2 | USE OF N-DESMETHYLCLOZAPINE AND RELATED COMPOUNDS AS DOPAMINE STABILIZING AGENTS | Arcadia Pharmaceuticals Inc. (US) | 2007-12-19 | — | — | EP | claimed |
| US-20070197502-A1 | AMINO SUBSTITUTED DIARYL[a,d]CYCLOHEPTENE ANALOGS AS MUSCARINIC AGONISTS AND METHODS OF TREATMENT OF NEUROPSYCHIATRIC DISORDERS | EK FREDRIK | 2007-08-23 | — | — | US | claimed |
| WO-2006107948-A9 | USE OF N-DESMETHYLCLOZAPINE AND RELATED COMPOUNDS AS DOPAMINE STABILIZING AGENTS | ACADIA PHARM INC (US) | 2007-02-22 | — | — | WO | claimed |
| US-20060252744-A1 | Use of N-desmethylclozapine and related compounds as dopamine stabilizing agents | ACADIA PHARMACEUTICALS INC. | 2006-11-09 | — | — | US | claimed |
| WO-2006107948-A2 | USE OF N-DESMETHYLCLOZAPINE AND RELATED COMPOUNDS AS DOPAMINE STABILIZING AGENTS | ACADIA PHARMACEUTICALS INC. (US) | 2006-10-12 | — | — | WO | claimed |
| US-20050192268-A1 | Amino substituted diaryl[a,d]cycloheptene analogs as muscarinic agonists and methods of treatment of neuropsychiatric disorders | ACADIA PHARMACEUTICALS INC. | 2005-09-01 | — | — | US | claimed |
| CN-103214473-A | Dibenzo[b,f][1,4]oxazapine compounds | ARYX THERAPEUTICS INC | 2013-07-24 | — | — | CN | disclosed |
| CN-101641350-B | Dibenzo [ b, f ] [1,4] oxazepine compounds | ARYX THERAPEUTICS INC | 2012-11-28 | — | — | CN | disclosed |
| US-20120178738-A1 | DIBENZO [B,F] [1,4]OXAZAPINE COMPOUNDS | ARYX THERAPEUTICS, INC. (US) | 2012-07-12 | — | — | US | disclosed |
| US-20120178738-A1 | DIBENZO [B,F] [1,4]OXAZAPINE COMPOUNDS | ARYX THERAPEUTICS, INC. (US) | 2012-07-12 | — | — | US | disclosed |
| EP-2137180-B1 | DIBENZO [B,F][1,4] OXAZAPINE COMPOUNDS | ARYX THERAPEUTICS INC (US) | 2012-03-07 | — | — | EP | disclosed |
| EP-2137180-B1 | DIBENZO [B,F][1,4] OXAZAPINE COMPOUNDS | ARYX THERAPEUTICS INC (US) | 2012-03-07 | — | — | EP | disclosed |
| US-20050192268-A1 | Amino substituted diaryl[a,d]cycloheptene analogs as muscarinic agonists and methods of treatment of neuropsychiatric disorders | ACADIA PHARMACEUTICALS INC. | 2005-09-01 | — | — | US | disclosed |
| EP-1406881-A1 | 11-PIPERAZINYLDIBENZO(B,F)(1,4)OXAZEPINES AND THIAZEPINES AS ATYPICAL ANTIPSYCHOTIC AGENTS HAVING LOW AFFINITY FOR THE D2 RECEPTOR | Neuromolecular, Inc. (CA) | 2004-04-14 | — | — | EP | disclosed |
| US-5602121-A | ANTISCHIZOPHRENIA AGENTS | ALLELIX BIOPHARMACEUTICALS, INC. (CA) | 1997-02-11 | — | — | US | disclosed |
| US-5602120-A | ADMINISTERING FOR TREATING A CONDITION MEDIATED BY THE D4 RECEPTOR: SCHIZOPHRENIA | ALLELIX BIOPHARMACEUTICALS, INC. (CA) | 1997-02-11 | — | — | US | disclosed |
| WO-1996018623-A1 | BENZYL-SUBSTITUTED COMPOUNDS HAVING DOPAMINE RECEPTOR AFFINITY | ALLELIX BIOPHARMACEUTICALS INC. (US) | 1996-06-20 | — | — | WO | disclosed |
| WO-1996018621-A1 | ALKYL-SUBSTITUTED COMPOUNDS HAVING DOPAMINE RECEPTOR AFFINITY | ALLELIX BIOPHARMACEUTICALS INC. (US) | 1996-06-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070197502-A1 | AMINO SUBSTITUTED DIARYL[a,d]CYCLOHEPTENE ANALOGS AS MUSCARINIC AGONISTS AND METHODS OF TREATMENT OF NEUROPSYCHIATRIC DISORDERS | CHRM4, CHRM5, CHRM1 | DRD2 29/4885CHRM1 3/4885HRH1 939/4885 |
| US-20060252744-A1 | Use of N-desmethylclozapine and related compounds as dopamine stabilizing agents | DRD3, DRD2, PNMT | DRD2 2/4885CHRM1 17/4885HRH1 1107/4885 |
| US-20120178738-A1 | DIBENZO [B,F] [1,4]OXAZAPINE COMPOUNDS | DBH, DRD4, PSEN1 | DRD2 7/4885CHRM1 493/4885HRH1 1821/4885 |
| US-20090239840-A1 | AMINO SUBSTITUTED DIARYL[a,d]CYCLOHEPTENE ANALOGS AS MUSCARINIC AGONISTS AND METHODS OF TREATMENT OF NEUROPSYCHIATRIC DISORDERS | CHRM4, CHRM5, CHRNA10 | DRD2 31/4885CHRM1 7/4885HRH1 913/4885 |
| US-20050192268-A1 | Amino substituted diaryl[a,d]cycloheptene analogs as muscarinic agonists and methods of treatment of neuropsychiatric disorders | CHRM4, CHRM5, CHRNA10 | DRD2 31/4885CHRM1 7/4885HRH1 913/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.